Clinical Trials
12 trialsNCT02234050 2025-07-10
Trabectedin for Recurrent Grade II/III Meningioma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03023124 2024-12-09
STRADA
Italian Sarcoma Group
Phase 2 Completed
NCT02247544 2021-11-01
TRAVELL
Italian Sarcoma Group
Phase 2 Completed
NCT02398058 2021-04-14
TOMAS
Italian Sarcoma Group
Phase 1 Completed
NCT02793050 2019-05-10
TrObs
Italian Sarcoma Group
Completed
NCT00070109 2018-09-14
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Children's Oncology Group
Phase 2 Completed
NCT00569673 2018-07-18
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
GOG Foundation
Phase 2 Completed
NCT02066675 2018-04-11
TR1US
Italian Sarcoma Group
Phase 2 Completed
NCT00379145 2017-12-12
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
GOG Foundation
Phase 2 Completed
NCT00006463 2014-02-21
Ecteinascidin 743 in Treating Children With Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT00003939 2012-09-24
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00002904 2012-07-02
Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed